News | Cybersecurity | Jeff Zagoudis, Associate Editor
Philips Healthcare last week issued a proactive advisory warning to its iSite and IntelliSpace picture archiving and communication system (PACS) customers of potential security vulnerabilities in the products. The company cautioned that while it has received no reports of patient harm, the vulnerabilities in question could impact or potentially compromise patient confidentiality, system integrity and/or system availability.
April 16, 2018
News | Defibrillator Monitors
The skin presents a formidable barrier to life-saving defibrillators, but a team of students from Rice University believes it has found a way around that problem.
April 16, 2018
Feature | Cath Lab | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating the ...
April 16, 2018Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Renal Denervation
Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral renal denervation system in patients with high blood pressure (hypertension). Renal denervation is a minimally invasive procedure intended to regulate the activity of nerves that lead to and from the kidney, which plays an important role in managing blood pressure. The SPYRAL HTN Pivotal Trial is part of the broader SPYRAL HTN Global Clinical Program, a multi-phased clinical study strategy aimed to establish the safety and efficacy of renal denervation to lower blood pressure.
April 16, 2018
Technology | Computed Tomography (CT)
Canon Medical Systems USA Inc. this week received U.S. Food and Drug Administration (FDA) clearance for the Aquilion Precision system, which it calls the world’s first Ultra-High Resolution computed tomography (UHR CT) system. The system can resolve anatomy as small as 150 microns and is designed to provide more than twice the resolution, typically seen only in cath labs. Containing an all-new detector as well as tube, gantry and reconstruction technologies, the system may make it possible to help expand visualization of disease thanks to new features that offer improved image detail.
April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears to ...
April 13, 2018Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo extracellular matrix (ECM) cardiovascular implantable electronic device (CIED) envelopes in the United States. BioEnvelope will be available from Biotronik starting in April 2018.
April 12, 2018News | Hemodynamic Support Devices
French medical technology company CorWave announced it has been awarded almost $3.5 million in financing for its R&D program NovaPulse in the Silver Economy category. This is part of phase 2 of France’s Concours Mondial d'Innovation or Worldwide Innovation Challenge.
April 12, 2018
News | Congenital Heart
Women who give birth to infants with congenital heart defects may have an increased risk of cardiovascular hospitalizations later in life, according to new research in the American Heart Association’s journal Circulation.
April 12, 2018Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News
Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF). The Arctic Front Advance Cyroablation System is not approved for treating persistent AF in the United States.
April 12, 2018
Blog | Cath Lab
The biggest workplace concern for interventional cardiologists and cath lab staff is their daily exposure to ionizing ...
April 12, 2018
Abbott today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by optical coherence tomography (OCT) compared to angiography. The trial (ILUMIEN IV) is the first large-scale randomized global study using Abbott's OCT imaging in patients with high-risk, complex coronary artery disease. Patients in the study will be randomized to either OCT-guided or traditional angiography to guide placement of one or more Xience everolimus-eluting coronary stents.
April 11, 2018Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Technology | Vascular Closure Devices
https://www.dicardiology.com/channel/vascular-closure-devicesCardiva Medical announced the company received U.S. Food and Drug Administration (FDA) approval for an expanded indication of the Vascade Vascular Closure System. Already approved for use in arterial closure, Vascade is now FDA-approved for use in 5-7F femoral venous closures as well. This expansion creates an opportunity to better treat patients undergoing interventional cardiac catheterization procedures, while also greatly increasing the available market for the device.
April 10, 2018
News | Heart Valve Technology
University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the first Intrepid transcatheter mitral valve replacement system in the study. Alan Markowitz, M.D., and Guilherme F. Attizzani, M.D., performed the procedure, the first in the state of Ohio.
April 06, 2018
News | Pharmaceuticals
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint with a statistically significant reduction in all-cause mortality plus frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified.1
April 06, 2018© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now